Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population. The purpose of this study is to determine whether clinical response seen in previous studies is replicable in this population.
A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
Saline at 0.9% intravenous infusion will be administered over 40 minutes.
Inclusion Criteria: Age: 18-65 years old Mayor Depressive Disorder Diagnosis based on DSM-IV TR. Classification of MDD as treatment-resistant. No brain structural abnormalities as evidenced by an MRI scan. Signed acceptance of Informed Consent. Exclusion Criteria: Other psychiatric diagnosis apart from MDD. Substance abuse or dependence (prior or during study). Pregnancy. Congestive heart disease. Personal history of psychosis. First-degree relative with history of psychosis. Glaucoma. Present neurological disease. High blood or pulmonary artery pressure. Declining the signing of the informed consent.